RareResearch.AI
← Back to atlas

D211N

Category 5 — IDR ExclusionPathogenic/Likely pathogenicCytoplasmic · predictedEditorial
AspartateAsparagine at position 211 · N-terminal cytoplasmic domain (87-313) · WFS1 (Wolframin)

Aspartate-to-asparagine substitution in a low-confidence region of the N-terminal cytoplasmic domain (pLDDT 44.56, below the IDR threshold) — the Atlas's structural framework cannot make confident claims here, and the schema correctly exits to wet-lab characterization.

Interactive 3D Structure

Wild-type reference
Wild-type D211 — hydrogen bond to N208
Fullscreen ↗
DynaMut2 mutant · D211N
Mutant N211 — energy-minimized; local contact network preserved
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

0 lost0 gained1 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondN208N208Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
0.67kcal/mol
Stabilising — mild
AlphaMissense
0.093
LBen
AlphaFold pLDDT
45
model confidence
Schema
Cat 5
Category 5 — IDR Exclusion
ΔΔG confidence: Reduced confidence · Cytoplasmic
  • pLDDT 44.56 below 70

The underlying AlphaFold model has pLDDT below 70 at this position, so the structure the stability calculation was run on is itself uncertain.

Do not rank this value against a variant from a different region on ΔΔG alone.

Clinical Evidence

ClinVar classificationPathogenic/Likely pathogenic
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditionsWolfram syndrome 1; Wolfram-like syndrome; Cataract 41; Autosomal dominant nonsyndromic hearing loss 6; Type 2 diabetes mellitus; Inborn genetic diseases
InheritanceInheritance pattern documented as both autosomal dominant (deafness 6) and within Wolfram-spectrum disorders.
Population frequency (gnomAD v4)Ultra-rare · AF 0.0018%
cDNA changec.631G>A
ClinVar accessionVCV000215378
Last evaluated2025/10/29 00:00

Observed at very low frequency in gnomAD.

Classified for2★ documented assertion

ClinVar classifies this variant as Pathogenic/Likely pathogenic for Cataract 41 (autosomal dominant, OMIM 116400); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); WFS1-related diabetes (autosomal dominant); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300); Wolfram-like syndrome (autosomal dominant, OMIM 614296). These are two clinically distinct disease families: classic Wolfram syndrome requires two affected copies, while the dominant WFS1-related disorders do not. One label covers both, and it does not tell you which applies to a given person.

  • Cataract 41autosomal dominant · OMIM 116400submitted as: Cataract 41
  • Nonsyndromic hearing loss (DFNA6/14/38)autosomal dominant · OMIM 600965submitted as: Autosomal dominant nonsyndromic hearing loss 6
  • WFS1-related diabetesautosomal dominantsubmitted as: Type 2 diabetes mellitus
  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1
  • Wolfram-like syndromeautosomal dominant · OMIM 614296submitted as: Wolfram-like syndrome
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 2★ multiple submitters, no conflicts. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.0018% · 29 / 1,612,016 alleles
Homozygotes
0
Highest-frequency population
European (non-Finnish) · AF 0.0023%

Highest in European (non-Finnish): AF 0.0023% (27 of 1,179,988 alleles), in line with the global figure.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
European (non-Finnish)0.0023%27 / 1,179,9880~1 in 21850
Remaining individuals · under-sampled0.0016%1 / 62,4540
African / African American · under-sampled0.0013%1 / 74,9220

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

D211 has only four neighbors within 5 Angstrom: Gly212 (2.43 Angstrom), His210 (2.45 Angstrom), Asn208 (4.57 Angstrom), and Glu209 (4.88 Angstrom). The minimal contact set and the low pLDDT are mutually reinforcing — both indicate that the local conformation is either intrinsically disordered or only weakly ordered in the AlphaFold ensemble. The structural inferences any computational pipeline would normally make at this resolution are not supported by the model.

The wild-type aspartate at 211 plausibly forms hydrogen bonds with H210 (an immediate neighbor whose imidazole could donate to the D211 carboxylate) and with E209 or N208 via secondary contacts. The D-to-N substitution removes the negative charge but preserves the hydrogen-bonding capacity; in fact, asparagine adds a hydrogen-bond donor (the amide NH2) where aspartate had only acceptors (the carboxylate oxygens). The net polar character is preserved but the electrostatic anchor is gone.

DynaMut2 reports DeltaDeltaG = +0.67 kcal/mol — stabilising and at the upper edge of the trustworthy bucket. AlphaMissense scores D211N at 0.093 (Likely Benign, well below the 0.564 threshold). Both computational metrics suggest the variant is structurally well-tolerated. The classification metadata explicitly flags this variant as not trustworthy for stability prediction because of the low pLDDT.

ClinVar nonetheless records D211N as Pathogenic/Likely pathogenic with multiple submitters across a broad phenotype spectrum (Cataract 41, AD hearing loss 6, type 2 diabetes, Wolfram syndrome 1, Wolfram-like syndrome). This is a third metric-discordant case in this batch — the structural and computational evidence argues against pathogenicity, while ClinVar curators have found clinical evidence for it. The reconciliation likely involves: (a) loss of an electrostatic anchor that the static AlphaFold model cannot evaluate because the region is dynamic, (b) ATP6V1A-binding interface disruption that affects function rather than fold, or (c) co-segregation with another variant in some families.

Amino-acid chemistry
Aspartate (negatively charged carboxylate side chain) to Asparagine (neutral amide side chain — same heavy-atom count and roughly the same volume, differing only in charge state and hydrogen-bonding profile) at position 211. The substitution is one of the most conservative possible chemistry-wise but removes the negative charge.
Position in the protein
Position 211 sits inside wolframin's N-terminal cytoplasmic domain (residues 87-313), within the UniProt-annotated ATP6V1A interaction region (residues 1-321). pLDDT 44.56 is below the IDR exclusion threshold (50) — the AlphaFold model is signaling that this region is likely disordered or has multiple conformations.

Druggability Assessment

Final classification: Category 5 — IDR Exclusion. The pLDDT (44.56) is below the structural confidence threshold; the schema correctly excludes D211N from the docking-and-structural-design pipeline and routes it to wet-lab characterization. The DynaMut2 metadata explicitly marks the stability prediction as not trustworthy for this position. This does not mean D211N is unimportant — the ClinVar phenotype breadth is substantial and the variant's recurrence across cataract, hearing loss, type 2 diabetes, and Wolfram-spectrum cases is clinically significant. It means that confident druggability assessment requires either an experimental structure of the local region, an NMR ensemble, or a functional assay (e.g., ATP6V1A-binding measurement) before therapeutic strategy can be designed. The Atlas's role here is to honestly identify the variant as one where structural-only inference is insufficient.

Why this matters

D211N is the canonical Category 5 case in this batch — a clinically important variant the Atlas's current framework cannot confidently characterize. The right scientific position is to acknowledge the limit. The Atlas's value to a clinical user is not undermined by saying this is where we need wet-lab data, it is enhanced. For the wolframin program, Category 5 variants like D211N are the experimental priority list. If the rare-disease research community can produce even modest functional data on D211N (an ATP6V1A binding assay, a cellular wolframin expression measurement, a cysteine modification profile), the Atlas can move D211N out of the exclusion bucket and into a defined category. Identifying which Category 5 variants are clinically common (D211N appears in multiple phenotype categories with multi-submitter ClinVar support) helps prioritize that experimental effort.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the D211N PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download D211N PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Region1321 · Interaction with ATP6V1A